Zobrazeno 1 - 10
of 44
pro vyhledávání: '"J.M. Vannetzel"'
Autor:
Robert Paridaens, Judith R. Kroep, John M. S. Bartlett, Annette Hasenburg, Daniel Rea, Christos Markopoulos, Gerrit-Jan Liefers, Caroline Seynaeve, Iris Noordhoek, Marjolijn Duijm-de Carpentier, Cornelis J.H. van de Velde, E.J. Blok, J.M. Vannetzel, Johanneke E.A. Portielje, Emiel J. Th. Rutgers, Hein Putter, Yasuo Hozumi, Elma Meershoek-Klein Kranenbarg
Publikováno v:
Journal of Clinical Oncology, 38(28), 3273-+. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(28), 3273-3281. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(28), 3273-3281. American Society of Clinical Oncology
PURPOSE Most distant recurrences (DRs) in women with hormone receptor–positive breast cancer occur after 5 years from diagnosis. The Clinical Treatment Score post-5 years (CTS5) estimates DRs after 5 years of adjuvant endocrine therapy (AET). The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::047202453994bf542be54716c3dd7c86
https://doi.org/10.1200/jco.19.02427
https://doi.org/10.1200/jco.19.02427
Autor:
Hein Putter, Daniel Rea, Robert Paridaens, Caroline Seynaeve, Elysée T.M. Hille, Johan W.R. Nortier, Christos Markopoulos, Yasuo Hozumi, Elma Meershoek-Klein Kranenbarg, Willemien van de Water, D.B.Y. Fontein, Peyman Hadji, John M. S. Bartlett, J.M. Vannetzel, Annette Hasenburg, Cornelis J.H. van de Velde, Stephen E. Jones
Publikováno v:
Journal of Clinical Oncology, 31(18), 2257-U59
Journal of Clinical Oncology, 31(18), 2257-U59. American Society of Clinical Oncology
Journal of Clinical Oncology, 31(18), 2257-U59. American Society of Clinical Oncology
Purpose Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d0259e2acd6903c59bc0fe6abada988
http://hdl.handle.net/1887/102052
http://hdl.handle.net/1887/102052
Autor:
J. Smeets, Daniel Rea, Annette Hasenburg, Johan W.R. Nortier, Dirk G. Kieback, Hein Putter, John M. S. Bartlett, Stephen E. Jones, E. T. M. Hille, Caroline Seynaeve, Robert Paridaens, Peyman Hadji, Yasuo Hozumi, J.M. Vannetzel, Christos Markopoulos, Lina Asmar, Cornelis J.H. van de Velde
Publikováno v:
Lancet (UK), 377(9762), 321-331. Elsevier Ltd.
BACKGROUND Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a26ba0b16d476aa36cd189c78d7cf5ba
https://pure.eur.nl/en/publications/eaf5d167-318e-479e-a456-e35176d28346
https://pure.eur.nl/en/publications/eaf5d167-318e-479e-a456-e35176d28346
Autor:
Caroline Seynaeve, D.W. Rea, D.B.Y. Fontein, Annette Hasenburg, Stephen E. Jones, Robert Paridaens, Christos Markopoulos, J.M. Vannetzel, P. Hadji, C.J.H. van de Velde
Publikováno v:
European Journal of Surgical Oncology. 38:758-759
Autor:
J.M. Vannetzel, Stephen E. Jones, Carine Seynaeve, Hein Putter, Annette Hasenburg, D.W. Rea, Robert Paridaens, C.J.H. van de Velde, W. van de Water, C. Markopoulos
Publikováno v:
European Journal of Cancer. 47:S334
Autor:
Stephen E. Jones, J.M. Vannetzel, D.W. Rea, Annette Hasenburg, Robert Paridaens, C. Markopoulos, Carine Seynaeve, C.J.H. van de Velde, Yasuo Hozumi, Hein Putter
Publikováno v:
European Journal of Cancer Supplements. 8:62
Autor:
D.W. Rea, Christos Markopoulos, Lina Asmar, R. Urbanski, Dirk G. Kieback, John M. S. Bartlett, Annette Hasenburg, Robert Paridaens, C.J.H. van de Velde, Stephen E. Jones, J.M. Vannetzel, J. Smeets, Caroline Seynaeve, Elysée T.M. Hille, Hein Putter, Yasuo Hozumi
Publikováno v:
Cancer Research. 69:11-11
Background: Exemestane (E) is a steroidal aromatase inhibitor (AI) with an established role in early breast cancer after 2–3 years of tamoxifen (T). Additionally, AIs have shown superiority to T as initial adjuvant therapy. The Tamoxifen Exemestane
Autor:
J.M. Vannetzel, J.G.H. van Nes, W.M. Meershoek-Klein Kranenbarg, Annette Hasenburg, Stephen E. Jones, C.J.H. van de Velde, C. Markopoulos, Carine Seynaeve, D.W. Rea, L Dirix
Publikováno v:
European Journal of Cancer Supplements. 7:301
Autor:
D.W. Rea, J.M. Vannetzel, J.W.R. Nortier, Stephen E. Jones, Robert Paridaens, J. Smeets, Carine Seynaeve, C.J.H. van de Velde, Annette Hasenburg, C. Markopoulos
Publikováno v:
European Journal of Cancer Supplements. 7:1
Autor:
Dirk G. Kieback, J. Smeets, J.M. Vannetzel, Yasuo Hozumi, Robert Paridaens, Elysée T.M. Hille, Hein Putter, C. Markopoulos, D Rae, R. Urbanski, Lina Asmar, Stephen E. Jones, Annette Hasenburg, Jms Bartlett, C.J.H. van de Velde, Carine Seynaeve
Publikováno v:
Cancer Research. 69:15
Abstract #15 Background: Exemestane (E) is a steroidal aromatase inactivator, which has been demonstrated to be more effective than tamoxifen (T) in metastatic breast cancer (BC). The role of E in adjuvant therapy has been established after 2 to 3 ye